All In Biotech

Drug Trial Radar · NCT05899673

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Actual

Start

Aug 8, 2023

Primary completion

May 2, 2033

Study completion May 2, 2033

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver. The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 \[NCT03945292\], AROAAT2002 \[NCT03946449\] , TAK-999-3001 \[NCT05677971\], or TAK-999-3002 \[NCT06165341\]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

Conditions

  • Alpha1-Antitrypsin Deficiency

Interventions

  • Fazirsiran InjectionDrug

    Fazirsiran will be injected subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
  2. Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function ParametersTime frame: Baseline (current study), up to EOS (current study up to 10 years])
  3. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
  4. Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • UCSD Altman Clinical and Translational Research Institute

    La Jolla, California

  • Stanford Medicine Outpatient Center

    Redwood City, California

  • UF Clinical and Translational Science Institute

    Gainesville, Florida

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa

  • Medical University of South Carolina - Hollings Cancer Center - PPDS

    Charleston, South Carolina

  • Medizinische Universitat Wien (Medical University of Vienna)

    Vienna, Austria

  • Universitätsklinikum der RWTH Aachen

    Aachen, North Rhine-Westphalia, Germany

  • Hospital Nélio Mendonça

    Funchal, Portugal

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Royal Infirmary of Edinburgh - PPDS

    Edinburgh, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.